Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Warning issued over eye exposure to ear drops
EMA said veterinary surgeons should advise pet owners to take care when applying Osurnia.
Reports of eye injuries in people and pets after accidental exposure 

The European Medicines Agency has issued a warning about accidental exposure to Osurnia ear gel for dogs, after a number of pets and owners suffered eye injuries.

Injuries reported in people include two cases of corneal ulcers, as well as complaints of eye irritation, conjunctivitis, redness, during, stinging and itchiness. In dogs, there were reports of corneal ulcers, squinting, impaired vision, conjunctivitis, redness and swelling around the eye.

Eye exposure in humans largely occurred when the dog shook its head during or just after the medication was applied to the ear.

Veterinary professionals will be informed about this issue in writing and are being encouraged to report any suspected side effects to the relevant national authority, or the manufacturer of Osurnia, Elanco Europe Ltd.

EMA said veterinary surgeons should advise pet owners to take care when applying Osurnia, taking appropriate measures to ensure the product does not contact the eyes of people or dogs. This includes restraining the animal’s head while the medicine is applied.

If accidental exposure does occur, rinse the eyes thoroughly with water for 10-15 minutes and seek medical care.

Pet owners should also monitor dogs treated with the product and contact their vet if they notice any side effects, particularly those affecting the eyes.

EMA says it will continue to monitor the safety of the medicine and will take regulatory action as appropriate.

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.